Tacalyx
Key Facts
| Invested since | 2019 |
| Based in | Berlin |
About the company
Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility of synthesizing these complex structures allows the production of specific antibodies for the treatment of currently unsatisfactorily treatable cancers.
Do you want to
know more about this company?
Tacalyx in the news
Zum Artikel
Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment
More startups from Life Sciences
Exit
c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either …
To the complete profileof c-LEcta
LignoPure GmbH is a spin-off of the TU Hamburg that enables the valorization of Lignin, a byproduct of ethanol biorefineries and the pulp and paper industry, via a proprietary technology. …
To the complete profileof LignoPure
Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, is pioneering computational pathology for pharmaceutical research and diagnostics. Its proprietary “Explainable AI” platform draws on …
To the complete profileof Aignostics
Lymphatica Medtech develops medical devices for lymphatic disease treatment. The first product, LymphoDRAIN, is the worldwide first active lymphatic bypass for the treatment of chronic lymphedema, a disabling disease affecting …
To the complete profileof Lymphatica
Innerspace develops novel, psychologically based training solutions for highly critical applications in the life science industry. Cleanroom operators are comprehensively prepared for the key moments of their work using the …
To the complete profileof innerspace
Exit
MYR, acquired by Gilead Sciences in 2021, developed a peptide-based, first-in-class drug to combat chronic hepatitis B and delta. The drug has been approved by the EMA for the treatment …
To the complete profileof MYR
AdvanceCOR is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative biologic drugs in acute vascular syndromes and have completed phase 2.
To the complete profileof AdvanceCOR
Resolve Biosciences is creating solutions which offer the power of Molecular Cartography enabling scientists to gain valuable insights at subcellular resolution, across vast numbers of biomolecules (RNA, DNA, proteins) to …
To the complete profileof Resolve Biosciences
TRIM TX is developing best-in-class Gamma-Secretase-Stabilizers (GSS) for the prevention and treatment of Alzheimer Disease.
To the complete profileof TRIM TX
hema.to is an easy-to-use software for clinical decision support for blood cancer from cytometry data using AI. hema.to makes the diagnostic workflow both faster and better, helping both diagnosticians as …
To the complete profileof hema.to
Sedivention is developing a medical device for a new therapy of obesity. The Blizzard cryocatheter freezes the nerve branches, that transmit an increased, inadequate feeling of hunger to the brain …
To the complete profileof Sedivention
Ebenbuild is a health tech pioneer that creates personalized treatment recommendations for mechanical ventilation and ICU patient care for clinical users. Founded in Munich in 2019, the company develops software …
To the complete profileof Ebenbuild